Skip to main content

Table 2 LV and LA parameters and on CMR patients: control subjects versus HCM; without adverse clinical events versus with combined outcome

From: Predictive value of left atrial strain analysis in adverse clinical events in patients with hypertrophic cardiomyopathy: a CMR study

Parameters

Control subjects (n = 89)

HCM population (n = 99)

p value

HCM patient without adverse clinical events (n = 81)

HCM patient with adverse clinical events (n = 18)

p value

LV parameters

      

Maximal LV thickness, mm

–

20.69 (18.67, 24.47)

–

20.53 (18.27, 24.06)

22.47 ± 4.41

0.611

LV EDVI, mL/m2

70.70 ± 10.61

77.77 (69.30, 87.04)

 < 0.001***

78.67 (68.75, 88.35)

74.03 (68.95, 84.95)

0.717

LV ESVI, mL/m2

26.54 ± 5.72

30.23 (25.68, 38.08)

 < 0.001***

29.73 (25.66, 36.77)

34.59 (25.75, 45.93)

0.292

LV EF, %

62.44 ± 6.05

59.88 (52.95, 65.74)

0.008**

60.55 (53.28, 65.79)

53.51 ± 13.26

0.147

LV SV, ml

84.06 ± 17.13

86.14 (72.85, 100.20)

0.310

87.92 (74.48, 105.69)

77.44 ± 20.81

0.030**

LV CO, L/min

5.57 (5.06, 6.62)

5.47 (4.47, 6.64)

0.337

5.69 (4.65, 6.81)

4.64 ± 1.24

0.005**

LV M, g

97.94 ± 19.22

165.25 (125.22,222.86)

 < 0.001***

161.79 (126.41, 220.79)

187.18 ± 78.45

0.877

LA volume and function

      

LA diameter, mm

39.82 ± 4.63

49.77 ± 6.87

 < 0.001***

49.34 ± 6.47

52.01 ± 8.41

0.218

LAV max, ml

77.02 ± 19.62

98.99 ± 27.35

 < 0.001***

95.69 ± 26.85

113.84 ± 25.19

0.010*

LAV pre-ac, ml

55.71 ± 14.91

81.18 ± 25.87

 < 0.001***

76.87 ± 24.59

92.05 (84.60, 112.41)

 < 0.001***

LAV min, ml

33.23 ± 10.53

55.86 ± 21.71

 < 0.001***

51.62 ± 19.33

74.90 ± 22.14

 < 0.001***

Total LAEF, %

57.16 ± 5.89

45.61 (39.06, 51.80)

 < 0.001***

46.99 ± 9.41

34.67 ± 9.29

 < 0.001***

Passive LAEF, %

27.15 ± 5.84

18.50 ± 8.23

 < 0.001***

20.07 ± 7.86

11.45 ± 5.94

 < 0.001***

Active LAEF, %

40.94 ± 5.38

34.34 (27.31, 38.29)

 < 0.001***

34.97 (29.08, 39.07)

26.17 ± 8.48

 < 0.001***

LA strain

      

GLS reservoir, %

32.10 (27.06, 37.42)

21.68 ± 7.19

 < 0.001***

23.129 ± 6.84

15.19 ± 4.83

 < 0.001***

GLS conduit, %

16.00 ± 4.35

8.95 (6.86, 12.84)

 < 0.001***

10.16 (7.32, 14.12)

6.04 ± 2.57

 < 0.001***

GLS booster, %

16.26 ± 3.20

11.57 ± 3.90

 < 0.001***

12.11 ± 3.81

9.15 ± 3.43

0.003**

GCS, %

34.57 ± 8.47

24.83 ± 10.13

 < 0.001***

26.67 ± 9.49

16.55 ± 8.90

 < 0.001***

LA strain rate

      

SR reservoir, s−1

1.12 ± 0.24

0.79 ± 0.25

 < 0.001***

0.83 ± 0.24

0.61 ± 0.21

0.001***

SR conduit, s−1

− 0.978 (− 1.28, − 0.81)

− 0.59 (− 0.81, − 0.44)

 < 0.001***

− 0.64 (− 0.85, − 0.50)

− 0.44 ± 0.20

 < 0.001***

SR booster, s−1

− 1.51 ± 0.33

− 1.00 ± 0.34

 < 0.001***

− 1.06 ± 0.32

− 0.72 ± 0.27

 < 0.001***

  1. Data were expressed as number (percentage), mean ± standard deviation, or median [interquartile range]
  2. LV, left ventricular; EDVI, end-diastolic volume index; ESVI, end-systolic volume index; EF, ejection fraction; SV, stroke volume; CO, cardiac output; M, myocardial mass; LA, left atrium; LAV, left atrial volume; LAEF, left atrial ejection fraction; GLS, global longitudinal strain; GCS, global circumferential strain; SR, strain rate
  3. “*”, “**”, and “***” reflect that the difference between groups is statistically significant
  4. “*” represents p < 0.05; “**” represents p < 0.01; “***” represents p < 0.001
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us